Perspective Therapeutics to Provide Business Highlights and Report Third Quarter 2024 Financial Results
Perspective Therapeutics (NYSE AMERICAN: CATX), a radiopharmaceutical company, will report its third quarter 2024 financial results and provide a business update on Tuesday, November 12, 2024 after the market closes. The press release will be available in the newsroom section of the Company's website.
Perspective Therapeutics (NYSE AMERICAN: CATX), un'azienda nel settore dei radiofarmaci, presenterà i suoi risultati finanziari per il terzo trimestre del 2024 e fornirà un aggiornamento aziendale il martedì 12 novembre 2024 dopo la chiusura del mercato. Il comunicato stampa sarà disponibile nella sezione newsroom del sito web dell'azienda.
Perspective Therapeutics (NYSE AMERICAN: CATX), una compañía de radiofármacos, reportará sus resultados financieros del tercer trimestre de 2024 y proporcionará una actualización del negocio el martes 12 de noviembre de 2024 después del cierre del mercado. El comunicado de prensa estará disponible en la sección de sala de prensa del sitio web de la compañía.
Perspective Therapeutics (NYSE AMERICAN: CATX), 방사성 의약품 회사는 2024년 3분기 재무 결과를 발표하고 2024년 11월 12일 화요일 시장 마감 후 사업 업데이트를 제공할 예정입니다. 보도 자료는 회사 웹사이트의 뉴스룸 섹션에서 확인할 수 있습니다.
Perspective Therapeutics (NYSE AMERICAN: CATX), une société de radionucléides, publiera ses résultats financiers du troisième trimestre 2024 et fournira une mise à jour sur les activités le mardi 12 novembre 2024 après la fermeture du marché. Le communiqué de presse sera disponible dans la section salle de presse du site web de l'entreprise.
Perspective Therapeutics (NYSE AMERICAN: CATX), ein Unternehmen für Radiopharmazeutika, wird am Dienstag, den 12. November 2024, nach Börsenschluss seine Finanzergebnisse für das dritte Quartal 2024 bekannt geben und ein Geschäftsupdate bereitstellen. Die Pressemitteilung wird im Nachrichtenbereich der Unternehmenswebsite verfügbar sein.
- None.
- None.
SEATTLE, Oct. 31, 2024 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective” or the “Company”) (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced treatment applications for cancers throughout the body, today announced that it will report its third quarter 2024 financial results and provide a business update on Tuesday, November 12, 2024 after the market closes. The press release will be available in the newsroom section of the Company's website at https://perspectivetherapeutics.com/newsroom/press-releases.
About Perspective Therapeutics, Inc.
Perspective Therapeutics, Inc. is a radiopharmaceutical development company that is pioneering advanced treatment applications for cancers throughout the body. The Company has proprietary technology that utilizes the alpha emitting isotope 212Pb to deliver powerful radiation specifically to cancer cells via specialized targeting peptides. The Company is also developing complementary imaging diagnostics that incorporate the same targeting peptides which provide the opportunity to personalize treatment and optimize patient outcomes. This "theranostic" approach enables the ability to see the specific tumor and then treat it to potentially improve efficacy and minimize toxicity.
The Company's melanoma (VMT01) and neuroendocrine tumor (VMT-α-NET) programs have entered Phase 1/2a imaging and therapy trials for the treatment of metastatic melanoma and neuroendocrine tumors at several leading academic institutions. The Company has also developed a proprietary 212Pb generator to secure key isotopes for clinical trial and commercial operations.
For more information, please visit the Company's website at www.perspectivetherapeutics.com.
FAQ
When will Perspective Therapeutics report its third quarter 2024 financial results?
Where can I find Perspective Therapeutics' third quarter 2024 financial results?
What is the stock symbol for Perspective Therapeutics?
What type of company is Perspective Therapeutics?
